Publications by authors named "Carmen F Bjurstrom"

Febrile seizures represent the most common type of pathological brain activity in young children and are influenced by genetic, environmental and developmental factors. In a minority of cases, febrile seizures precede later development of epilepsy. We conducted a genome-wide association study of febrile seizures in 7635 cases and 83 966 controls identifying and replicating seven new loci, all with P < 5 × 10-10.

View Article and Find Full Text PDF

We examined the efficiency, specificity, and mutational signatures of zinc finger nucleases (ZFNs), transcriptional activator-like effector nucleases (TALENs), and clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 systems designed to target the gene encoding the transcriptional repressor BCL11A, in human K562 cells and human CD34 progenitor cells. ZFNs and TALENs were delivered as in vitro transcribed mRNA through electroporation; CRISPR/Cas9 was codelivered by Cas9 mRNA with plasmid-encoded guideRNA (gRNA) (pU6.g1) or in vitro transcribed gRNA (gR.

View Article and Find Full Text PDF

Infantile malignant osteopetrosis (IMO) is a rare, recessive disorder characterized by increased bone mass caused by dysfunctional osteoclasts. The disease is most often caused by mutations in the TCIRG1 gene encoding a subunit of the V-ATPase involved in the osteoclasts capacity to resorb bone. We previously showed that osteoclast function can be restored by lentiviral vector-mediated expression of TCIRG1, but the exact threshold for restoration of resorption as well as the cellular response to vector-mediated TCIRG1 expression is unknown.

View Article and Find Full Text PDF
Article Synopsis
  • Targeted genome editing technologies, including TALENs and CRISPR/Cas9, can effectively correct the sickle cell disease mutation in the β-globin gene within hematopoietic stem cells.
  • The correction allows for the production of red blood cells that produce normal hemoglobin proteins instead of the abnormal ones associated with sickle cell disease.
  • In experiments with patient-derived CD34+ cells, CRISPR/Cas9 led to over 18% gene modification and successfully corrected the mutation, demonstrating its potential for treating this genetic disorder.
View Article and Find Full Text PDF